ARCHIVES

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

This article is from The Cancer Letter archive.

Vol. 31 No. 22 | June 3, 2005

Download PDF Visit The Full Archive

Related Articles

FY2000 Appropriations: NIH Gets $17.9 Billion, A 15% Increase, In Final Budget Agreement; $3 billion to Be Delayed

November 26, 1999

Immune Therapy Possible For Metastatic Breast Cancer

September 24, 2004

UICC Announces Four Grant award Programs

July 14, 1978

Hyperthermia, Radiation Enhancement, New Drugs Offer More Therapy Advances, ASCO Members Hear

April 7, 1978

NSABP Agrees To Three-Month Search for Chairman Candidates, Review Of Plans

June 10, 1994

Letter to the Editor

March 21, 2003